<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711811</url>
  </required_header>
  <id_info>
    <org_study_id>HBCMP01</org_study_id>
    <nct_id>NCT04711811</nct_id>
  </id_info>
  <brief_title>Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Musculoskeletal Pain</brief_title>
  <acronym>CMP</acronym>
  <official_title>&quot;Individual Patient Expanded Access IND Using HB-adMSCs for the Treatment of Chronic Musculoskeletal Pain.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hope Biosciences Stem Cell Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hope Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hope Biosciences</source>
  <brief_summary>
    <textblock>
      This is an Individual Patient Expanded Access IND providing multiple administrations of&#xD;
      HBadMSCs for the treatment of Chronic Musculoskeletal Pain. The study duration is&#xD;
      approximately 32 weeks, during that time the study subject will complete 1 screening visit, 6&#xD;
      infusion visits, one follow-up visit without infusion and one end of study visit. Next day&#xD;
      telephone follow-up visits will occur following each infusion. Efficacy and safety labs as&#xD;
      well as quality of life and VAS scores will be obtained.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Chronic Pain</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HB-adMSC</intervention_name>
    <description>Hope Biosciences adipose derived autologous mesenchymal stem cell product</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subject is &gt; 18 years of age at the time of signing the informed consent form.&#xD;
&#xD;
             2. Subject has the diagnosis of chronic musculoskeletal pain for a least 1 year or VAS&#xD;
             score &gt; 7 a screening visit. 3. Subject has provided informed consent before&#xD;
             initiation of any study procedure.&#xD;
&#xD;
             4. Subject and sexual partner if woman of childbearing potential must use a least 1&#xD;
             highly effective form of birth control* throughout the study and for 6 months after&#xD;
             the last dose of the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subject has any active infection for which antibiotics were indicated within 4&#xD;
             weeks before screening. 2. Subject has known alcoholic addiction or dependency, uses&#xD;
             alcohol daily, or has current substance use or abuse. 3. Subject has any active&#xD;
             malignancy, including evidence of cutaneous basal, squamous cell carcinoma, or&#xD;
             melanoma. 4. Subject has 1 or more significant concurrent medical conditions per&#xD;
             investigator judgment, including the following:&#xD;
&#xD;
          -  poorly controlled diabetes.&#xD;
&#xD;
          -  chronic kidney disease&#xD;
&#xD;
          -  heart failure&#xD;
&#xD;
          -  myocardial infarction or unstable angina within 6 months prior to screening.&#xD;
&#xD;
          -  uncontrolled hypertension 5. Subject has received any stem cell treatment within 12&#xD;
             months before first dose of investigational product. 6. Subject has laboratory&#xD;
             abnormalities during screening, including the following:&#xD;
&#xD;
          -  White blood cell count &lt; 3000/mm3&#xD;
&#xD;
          -  Platelet count &lt; 125,000mm3&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1500/mm3&#xD;
&#xD;
          -  Subject has any other laboratory abnormality, which, in the opinion of the&#xD;
             investigator poses a safety risk or will prevent the subject for completing the study.&#xD;
&#xD;
             7. Subject is currently receiving treatment in another investigational drug study.&#xD;
&#xD;
             8. Subject is unlikely to complete the study or adhere to the study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Djamchid Lotfi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Biosciences Stem Cell Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hope Biosciences Stem Cell Research Foundation</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Pain</keyword>
  <keyword>trauma</keyword>
  <keyword>Pain</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Autologous MSCs</keyword>
  <keyword>MSCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

